Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
ATO MM
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Preventive Treatment of Menstrual Migraine
2 other identifiers
interventional
430
12 countries
95
Brief Summary
A migraine attack is a moderate or severe headache that usually occurs on one side of the head and is often throbbing or pulsating. The headache is often accompanied by sensitivity to light, sensitivity to sound, nausea, or other symptoms. Menstrual migraine (MM) attacks are migraine attacks that occur in individuals before or during their menstrual period. The main goals of the study are to evaluate the efficacy (how well the medicine works), safety, and tolerability (the degree to which any adverse symptoms can be handled by the patients during the study) of atogepant, compared to placebo (looks like the study treatment but has no medicine in it), for the prevention of MM. Atogepant is an investigational drug being developed for the preventive treatment of menstrual migraine. Participants are randomly assigned to one of the 2 treatment groups called Arms to receive atogepant or matching placebo. There is 1 in a 2 chance for the participant to receive placebo. Approximately 430 adult female participants with menstrual migraine will be enrolled in approximately 85 sites across the world. Participants will receive oral atogepant or matching placebo for 3 menstrual cycles during the double-blind period. During the open-label treatment period, participants will receive atogepant during each menstrual cycle. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The safety and tolerability of the treatment will be checked by medical assessments, blood tests, checking for adverse events and completing questionnaires.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_3
Started Feb 2025
95 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 29, 2025
CompletedFirst Posted
Study publicly available on registry
February 4, 2025
CompletedStudy Start
First participant enrolled
February 10, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
July 1, 2027
March 6, 2026
March 1, 2026
2 years
January 29, 2025
March 4, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in Number of Migraine Days Occurring During the Perimenstrual Period (PMP)
A migraine day is defined as any calendar day on which a headache occurs which meets criteria listed, as per participant eDiary.
Up to approximately 120 days
Secondary Outcomes (7)
Change in Number of Migraine Days (With Moderate or Severe Headache) During the PMP
Up to approximately 120 days
Percentage of Participants Achieving >= 50% Reduction in Number of Migraine Days Averaged Across 3 PMPs
Up to approximately 120 days
Change in Number of Acute Medication Use Days During PMP
Up to approximately 120 days
Change in Number of Moderate or Severe Headache Days During PMP
Up to approximately 120 days
Percentage of Participants Achieving 100% Reduction From Baseline in Number of Migraine Days Averaged Across 3 PMPs
Up to approximately 120 days
- +2 more secondary outcomes
Study Arms (2)
Atogepant
EXPERIMENTALParticipant will receive atogepant during Double-Blind period and Open-Label period.
Placebo for Atogepant
PLACEBO COMPARATORParticipant will receive placebo during Double-Blind period and atogepant during the Open-Label period.
Interventions
Eligibility Criteria
You may qualify if:
- History and eDiary confirmation have regular menstrual cycles within the range of 21 to 35 days in length (Note: menstrual cycle length is calculated as onset of menses until the day before the next onset of menses).
- History of migraine (with or without aura) according to the International Classification of Headache Disorders, 3rd Edition (ICHD-3) for \>= 12 months prior to Visit 1/Screening.
- Migraine onset before age 50 years.
- By history at Visit 1/Screening, participant meets ICHD-3 criteria for pure menstrual migraine with or without aura, or menstrually-related migraine with or without aura, i.e., in at least 2 out of 3 cycles, experiences migraine attacks starting during the PMP (Day -2 to Day +3 relative to menses onset) in the opinion of the investigator.
- Participant records 3 perimenstrual periods (PMP) in the eDiary during the screening period, and in at least 2 of 3 PMPs the participant experiences and records a migraine attack in the eDiary with at least 1 migraine day.
You may not qualify if:
- History of an average of 15 or more headache days per month during the 3 months prior to Visit 1/Screening per the investigator's judgment, or a current diagnosis of chronic migraine as defined by International Classification of Headache Disorders, 3rd Edition (ICHD-3).
- An average of 15 or more headache days per month recorded in the eDiary during the screening period.
- History of migraine with brainstem aura, hemiplegic migraine, or retinal migraine as defined by ICHD-3.
- Current diagnosis of new persistent daily headache, trigeminal autonomic cephalalgia (e.g., cluster headache), or painful cranial neuropathy as defined by ICHD-3.
- Required hospital/emergency room treatment for migraine attacks 3 or more times within 6 months prior to Visit 1/Screening.
- Presence of other confounding pain syndromes, confounding psychiatric conditions, dementia, epilepsy, or significant neurological disorders other than migraine per investigator judgment.
- Has a condition or situation, which the investigator feels will compromise the safety of the participant or the quality of the data and renders the subject an unsuitable candidate for the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AbbVielead
Study Sites (95)
Chinese PLA General Hospital /ID# 267141
Beijing, Beijing Municipality, 100039, China
Nanfang Hospital - Southern Medical University /ID# 268510
Guangzhou, Guangdong, 510000, China
Hebei General Hospital /ID# 267663
Shijiazhuang, Hebei, 500051, China
Renmin Hospital of Wuhan University /ID# 267671
Wuhan, Hubei, 430060, China
The First Affiliated Hospital of Soochow University /ID# 267885
Suzhou, Jiangsu, 215006, China
Shaanxi Provincial PeopleS Hospital /ID# 267827
Xi'an, Shaanxi, 710054, China
First Affiliated Hospital of Shanxi Medical University /ID# 267680
Taiyuan, Shanxi, 030001, China
Tianjin Medical University General Hospital /ID# 268846
Tianjin, Tianjin Municipality, 300052, China
Tianjin People's Hospital /ID# 268511
Tianjin, Tianjin Municipality, 300120, China
The Second Affiliated Hospital of Zhejiang University School of Medicine /ID# 267994
Hangzhou, Zhejiang, 310009, China
A-Shine s.r.o. /ID# 266048
Pilsen, Plzeň Region, 301 00, Czechia
Vseobecna Fakultni Nemocnice v Praze /ID# 268100
Prague, Praha 17, 128 00, Czechia
DADO MEDICAL s.r.o. /ID# 267629
Prague, Praha 2, 120 00, Czechia
MINKSneuro s.r.o /ID# 267651
Brno, 615 00, Czechia
Neurologie Brno /ID# 266050
Brno, 616 00, Czechia
NeuroHK s.r.o. /ID# 266051
Hradec Králové, 500 09, Czechia
Neuro plus s.r.o. /ID# 266052
Olomouc, 775 00, Czechia
Clintrial s.r.o. /ID# 266047
Prague, 100 00, Czechia
Pratia Prague s.r.o. /ID# 268252
Prague, 130 00, Czechia
Fakultni Thomayerova nemocnice /ID# 266049
Prague, 140 59, Czechia
Neuro Centrum Odenwald - Praxis Erbach /ID# 276171
Erbach im Odenwald, Hesse, 64711, Germany
Studienzentrum Nord-West /ID# 267311
Westerstede, Lower Saxony, 26655, Germany
Universitaetsmedizin Greifswald /ID# 267277
Greifswald, Mecklenburg-Vorpommern, 17489, Germany
Neurozentrum Bielefeld /ID# 276170
Bielefeld, North Rhine-Westphalia, 33647, Germany
Klinikum Ibbenbueren /ID# 267393
Ibbenbueren, North Rhine-Westphalia, 49477, Germany
ZNS Siegen /ID# 268247
Siegen, North Rhine-Westphalia, 57076, Germany
Pharmakologisches Studienzentrum Chemnitz GmbH /ID# 267285
Chemnitz, Saxony, 09111, Germany
Ambenet Hausarztpraxis /ID# 267309
Leipzig, Saxony, 04107, Germany
Charite Universitaetsmedizin Berlin - Campus Mitte /ID# 267310
Berlin, 10117, Germany
MIND Clinic /ID# 267652
Budapest, 1024, Hungary
Cortex Study Center /ID# 266639
Budapest, 1026, Hungary
Clinexpert Kft /ID# 266644
Budapest, 1033, Hungary
Semmelweis Egyetem /ID# 266636
Budapest, 1085, Hungary
Semmelweis Egyetem /ID# 266752
Budapest, 1085, Hungary
UNO Medical Trials /ID# 266643
Budapest, 1135, Hungary
S-Medicon Kft /ID# 266637
Budapest, 1138, Hungary
Uzsoki Utcai Kórház /ID# 266641
Budapest, 1145, Hungary
Azienda Ospedaliero Universitaria Careggi /ID# 276163
Florence, Firenze, 50134, Italy
Fondazione IRCCS Istituto Neurologico Carlo Besta /ID# 267062
Milan, Milano, 20133, Italy
Istituto Auxologico Italiano - Ospedale San Luca /ID# 276161
Milan, Milano, 20149, Italy
Azienda Ospedaliera Universitaria Luigi Vanvitelli /ID# 267023
Naples, Napoli, 80138, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Universita Cattolica /ID# 266859
Rome, Roma, 00168, Italy
ICOT Istituto Marco Pasquali /ID# 267288
Latina, 04100, Italy
Fondazione Mondino Istituto Neurologico Nazionale a Carattere Scientifico IRCCS /ID# 267922
Pavia, 27100, Italy
Azienda Ospedaliera di Perugia - Ospedale S. Maria della Misericordia /ID# 267926
Perugia, 06156, Italy
ASU FC - P.O. Universitario Santa Maria della Misericordia /ID# 267019
Udine, 33100, Italy
Konan Medical Center /ID# 266867
Kobe, Hyōgo, 658-0064, Japan
Fujitsu Clinic /ID# 266877
Kawasaki-shi, Kanagawa, 211-8588, Japan
Umenotsuji Clinic /ID# 266834
Kochi, Kochi, 780-8011, Japan
Sendai Headache and Neurology Clinic Medical Corporation /ID# 266864
Sendai, Miyagi, 982-0014, Japan
Ooba Clinic For Neurosurgery & Headache /ID# 266866
Ōita, Oita Prefecture, 870-0831, Japan
Chibune General Hospital /ID# 266874
Osaka, Osaka, 555-0034, Japan
Tominaga Clinic - Osaka /ID# 268228
Osaka, Osaka, 556-0015, Japan
Usuda Clinic Of Internal Medicine /ID# 266870
Setagaya-ku, Tokyo, 156-0043, Japan
Tokyo Headache Clinic /ID# 266863
Shibuya-ku, Tokyo, 151-0051, Japan
Nagaseki Headache Clinic /ID# 266865
Kai, Yamanashi, 400-0124, Japan
Solumed Centrum Medyczne /ID# 267220
Poznan, Greater Poland Voivodeship, 60-529, Poland
Athleticomed Sp. z o.o /ID# 266434
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, 85-752, Poland
SPZOZ Szpital Uniwersytecki w Krakowie /ID# 266443
Krakow, Lesser Poland Voivodeship, 31-501, Poland
Instytut Zdrowia Dr Boczarska Jedynak /ID# 266073
Oświęcim, Lesser Poland Voivodeship, 32-600, Poland
Centrum Badan Klinicznych PI-House sp. z o.o. /ID# 266732
Gdansk, Pomeranian Voivodeship, 80-546, Poland
Novo-Med Zielinski i wspolnicy SP. J. /ID# 266433
Katowice, Silesian Voivodeship, 40-584, Poland
Neuro-Care Sp. z o.o. sp.k /ID# 267883
Katowice, Silesian Voivodeship, 40-749, Poland
MIGRE Polskie Centrum Leczenia Migreny Anna Gryglas-Dworak /ID# 266437
Wroclaw, 52-210, Poland
Unidade Local de Saude do Alto Ave, EPE /ID# 266168
Guimarães, Braga District, 4835-044, Portugal
Hospital da Luz /ID# 266182
Lisbon, Lisbon District, 1500-650, Portugal
Unidade Local de Saude de Loures-Odivelas, EPE /ID# 266190
Loures, Lisbon District, 2674-514, Portugal
Unidade Local de Saude de Matosinhos, EPE /ID# 266170
Senhora da Hora, Porto District, 4464-513, Portugal
Unidade Local de Saude de Almada-Seixal, EPE /ID# 276215
Almada, Setúbal District, 2805-267, Portugal
Unidade Local de Saude da Regiao de Aveiro, EPE /ID# 266187
Aveiro, 3814-501, Portugal
2CA-Braga, Hospital de Braga /ID# 276218
Braga, 4710-243, Portugal
Unidade Local de Saude de Santa Maria, EPE /ID# 275932
Lisbon, 1649-035, Portugal
Unidade Local de Saude Sao Joao, EPE /ID# 266185
Porto, 4200-319, Portugal
Unidade Local de Saude da Arrabida, EPE /ID# 266183
Setúbal, 2910-446, Portugal
Hallym University Dongtan Sacred Heart Hospital /ID# 267473
Hwaseong, Gyeonggido, 18450, South Korea
Nowon Eulji Medical Center, Eulji University /ID# 267474
Seoul, Seoul Teugbyeolsi, 01830, South Korea
Seoul National University Hospital /ID# 267477
Seoul, Seoul Teugbyeolsi, 03080, South Korea
Kangbuk Samsung Hospital /ID# 267475
Seoul, Seoul Teugbyeolsi, 03181, South Korea
Yonsei University Health System Severance Hospital /ID# 267476
Seoul, Seoul Teugbyeolsi, 03722, South Korea
Hospital Universitari Vall d'Hebron /ID# 276467
Barcelona, 08035, Spain
Hospital Clinic de Barcelona /ID# 276468
Barcelona, 08036, Spain
Hospital Clinico San Carlos /ID# 275896
Madrid, 28040, Spain
Hospital Universitario La Paz /ID# 276332
Madrid, 28046, Spain
Hospital Clinico Universitario de Valladolid /ID# 275899
Valladolid, 47003, Spain
China Medical University Hospital /ID# 266423
Taichung, 40447, Taiwan
National Cheng Kung University Hospital /ID# 267754
Tainan, 704, Taiwan
Mackay Memorial Hospital /ID# 266421
Taipei, 104, Taiwan
Taipei Veterans General Hospital /ID# 266418
Taipei, 112, Taiwan
Linkou Chang Gung Memorial Hospital /ID# 266424
Taoyuan, 333, Taiwan
Royal Sussex County Hospital /ID# 268362
Brighton, East Sussex, BN2 5BE, United Kingdom
St Pancras Clinical Research /ID# 268653
London, Greater London, EC2Y 8EA, United Kingdom
Guy's Hospital /ID# 267587
London, Greater London, SE1 9RT, United Kingdom
Breckland Alliance /ID# 268772
Thetford, Norfolk, IP24 1JD, United Kingdom
Oxford University Hospitals - John Radcliffe Hospital /ID# 267659
Oxford, Oxfordshire, OX3 9DU, United Kingdom
The Adam Practice /ID# 268116
Poole, BH16 5PW, United Kingdom
Related Links
MeSH Terms
Interventions
Study Officials
- STUDY DIRECTOR
ABBVIE INC.
AbbVie
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 29, 2025
First Posted
February 4, 2025
Study Start
February 10, 2025
Primary Completion (Estimated)
February 1, 2027
Study Completion (Estimated)
July 1, 2027
Last Updated
March 6, 2026
Record last verified: 2026-03
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP
- Time Frame
- For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/
- Access Criteria
- To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.